The purpose of this study is to test if the addition of a drug called H.P. Acthar® (Repository Corticotropin Injection) to current FSGS therapy will have beneficial effects on transplanted kidney function by decreasing the amount of protein excreted through your kidney over time. Acthar is currently FDA approved for the treatment of infantile spasms in infants and children under 2 years of age and for the treatment of exacerbation of multiple sclerosis in adults, but it has not been studied specifically in transplant patients.
Screening, Study Visits: Weeks 1, 4, 8, 12, 16, 20, 24, 36 and 52. 24 Hr Urine collection (3) Lab draws at each visit. Acthar injection 2x/week for weeks 1 thru 24. After the first injection you may begin receiving these injections at home when you feel comfortable.
Contact the study team for details
Surgery - Transplant
Clinical or Medical
Kidneys and Liver